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Previews
supported by a report in press confirming an essentialIronic Fate: Can a Banned Drug
role for iron in MPTP toxicity (Kalivendi et al., 2003) andControl Metal Heavies very recent evidence for increased oxidative stress in
the brains of hemizygous H ferritin null mice (Thompsonin Neurodegenerative Diseases?
et al., 2003). Appropriate sequestration of iron is an
increasingly compelling target for limiting oxidative
damage, especially for prevention. In the case of PD,
early detection and more effective intervention may beIn this issue of Neuron, Kaur et al. demonstrate that
possible, combining very early clinical changes (olfac-iron chelation by ferritin transgene or the metal chela-
tory dysfunction, depression, changes in handwriting ortor clioquinol prevent oxidative damage and MPTP
speech, or reduced ambulatory arm motion) with newtoxicity in mice. This raises the issue of specific iron
techniques for imaging the nigral iron accumulation thatchelators or clioquinol for control of oxidative damage
precedes major clinical deficits (Becker et al., 2002).in Parkinson’s, Alzheimer’s, and other neurodegenera-
Alzheimer’s Disease (AD)tive diseases, but not without safety concerns.
Chelation therapy with CQ has also shown evidence of
significant protective effects in an amyloid precursorFree radical damage has long been implicated in the
protein (APP) transgenic model for AD, dramatically re-chronic diseases of aging, including devastating neuro-
ducing amyloid accumulation, an effect believed to belogical disorders like amyotrophic lateral sclerosis,
due to chelation of zinc ions destabilizing plaquesstroke, Alzheimer’s (AD) and, perhaps most clearly, Par-
(Cherny et al., 2001). In that study, no attempt was madekinson’s disease (PD). Control of free radical damage
to show a CQ effect on the limited neurodegenerationhas been primarily attempted by manipulating oral anti-
in the APP transgenics or the oxidative damage that isoxidant intake and levels of defense enzymes. Limited
clearly present in AD and in the model (Pratico et al.,success has been obtained in clinical trials with vitamin
2001). However, an improvement in behavioral symp-E, but because trials have not gauged the control of
toms was observed. Because of the critical role of ironoxidative damage, it remains unclear how significant a
in oxidative damage, the present results of Kaur et al.
target oxidative damage really is. Because of toxicity
suggest that, like the antioxidant curcumin (Lim et al.,
concerns, less attention has been given to reducing
2001), CQ has the potential to suppress both amyloid
radical production by control of the transition metal cat-
and oxidative damage, two very well-established factors
alysts (notably Cu2 and Fe2) that are responsible for
in AD pathogenesis. Based on this and other evidence
converting less reactive superoxide and hydrogen per-
for the involvement of metals in amyloidosis and AD, a
oxide into highly reactive species like hydroxyl radical. phase II double-blinded clinical trial on AD patients in
Whether a cause or consequence of the disease, iron Australia has been carried out by Masters and col-
levels are clearly elevated in the substantia nigra (SN) leagues. While some indication of initial positive results
of PD patients where dopamine deamination by mono- in the trial have been presented at a meeting cited by
amine oxidase generates excess hydrogen peroxide. In Kaur et al., the website of the sponsoring company,
this issue of Neuron, Julie Andersen at the Buck Institute Prana, cautiously states that the results “continue to be
and collaborators have addressed the possibility of a analyzed.” The same website also notes an ongoing
causal role for iron in the loss of dopaminergic cells in open label extension with CQ in AD patients, consistent
a Parkinson’s model (Kaur et al., 2003). They suppressed with possible benefits and limited, if any, adverse events.
the levels of reactive ferrous iron either by transgenic A Note of Caution
expression of the specific iron binding protein ferritin or Kaur and colleagues conclude that “nontoxic iron chela-
by administration of a small bioavailable metal chelator tion may be an effective therapy for prevention and treat-
(clioquinol, CQ). For the transgenic mice, the investiga- ment of the disease.” For prevention this is very likely
tors used a tyrosine hydroxylase promoter to drive ferri- true, provided that the chelation therapy is truly non-
tin expression in dopaminergic cells that are damaged toxic. First, because of the critical metabolic roles of
or lost after repeated injections of 1-methyl-4-phenyl- essential minerals, specificity (achieved with ferritin) has
1,2,3,6-tetrapyridine (MPTP) in control wild-type mice. The been considered highly desirable to avoid depletion by
results show that both the ferritin transgenics and CQ- chronic therapy in conditions with metal overload. As
treated wild-type mice had reduced SN-reactive iron Kaur et al. point out, unlike deferrioxamine and other
levels and limited MPTP-induced losses in reduced glu- currently used iron chelators, CQ does not result in
tathione, dopamine, and dopaminergic cell numbers. depletion of systemic iron levels. This should make it
MPTP-induced behavioral deficits assessed by rotorod much less likely to produce depletion-related side ef-
(transgenics) or motor activity (CQ treatment) were also fects. The second toxicity issue is the potential for prob-
ameliorated. The beneficial effects were attributed to lems from the free chelator itself or metal-chelate com-
control of oxidative damage demonstrated by a sup- plexes that may have both anti- and pro-oxidant effects,
pression of reactive oxygen species in ferritin trans- depending on their dose and interactions with regener-
genics and CQ-induced reductions in proteins with oxi- ating antioxidants. One needs to be especially cautious
dative damage (carbonyls, 4-hydroxynonenal). because three decades ago CQ was withdrawn from
the market after its use was linked to some 10,000 casesThe Andersen group’s promising in vivo results are
Neuron
890
Pratico, D., Uryu, K., Leight, S., Trojanowski, J.Q., and Lee, V.M.of a subacute myelo-neuropathy (SMON), primarily in
(2001). J. Neurosci. 21, 4183–4187.Japan (Tabira, 2001; Tateishi, 2000). CQ iron chelates
Tabira, T. (2001). Science 292, 2251–2252.were initially implicated because they were found in
Tateishi, J. (2000). Neuropathology Suppl. 20, S20–S24.urine of SMON patients and shown to increase lipid
Thompson, K., Menzies, S., Muckenthaler, M., Torti, F.M., Wood,peroxidation. Further, SMON symptoms and distal
T., Torti, S.V., Hentze, M.W., Beard, J., and Connor, J. (2003). J.axonopathy could be reproduced with high-dose CQ
Neurosci. Res. 71, 46–63.administration to dogs and cats with marked variation
Young, I.S., Tate, S., Lightbody, J.H., McMaster, D., and Trimble,in the response due to dose and species (Matsuki et
E.R. (1995). Free Radic. Biol. Med. 18, 833–840.
al., 1997). More recent findings have led to the hypothe-
sis that CQ zinc chelates were the neurotoxin involved
in SMON (Arbiser et al., 1998). As with most drugs, toxic-
ity may occur at very high doses, but for useful agents,
not within their effective therapeutic window. Because Interpolating between Cellularof the potential oxidative damage from metal chelates,
Biophysics and Computationtheir use may require appropriate dietary or supple-
mentary antioxidants that were inadequate in postwar in Single Neurons
Japan. For example, for deferrioxamine to control oxida-
tive damage in diabetic rats, an ascorbic acid supple-
ment was required (Young et al., 1995). An alternative
theory discussed by Kaur et al. is that indiscriminate What types of computations are performed on synap-
high-dose CQ use aggravated B12 deficiency in postwar tic inputs within the dendritic trees of single neurons?
Japan and led to SMON in a subset of vulnerable pa- In this issue of Neuron, Poirazi et al. (2003a, 2003b)
tients. They have found no evidence for CQ toxicity with present a systematic method to reduce complex, bio-
effective dosing in mice. More significantly, in a phase physically realistic neuron models to more tractable,
II clinical trial, therapeutic CQ has been coadministered simplified two-layered neural networks that could
with B12 to Alzheimer patients with no evidence of drug- shed some light on this issue.
dependent adverse events. Whether or not the toxicity
issues with CQ can be ironed out, Andersen and col- The complexity of synaptic integration mechanisms
leagues’ work with the ferritin transgenics provides within single neurons has become mind-boggling fol-
strong evidence that control of oxidative damage by lowing the explosive increase in databases on dendritic
nontoxic iron chelation may be a viable approach for PD recordings in slice preparations during the past decade
and perhaps other neurodegenerative diseases. Based on (Stuart et al., 1999; Reyes, 2001). Yet, to understand
its success in animal models for both AD and PD and its how ionic channels and their distribution are utilized by
apparent safety and possible efficacy in the clinic with single cells to process information will require some
AD patients, there is growing reason for the ironic hope abstraction from biophysical detail toward simpler mod-
that the drug CQ, once withdrawn from the market for els and a shift in focus from a faithful description to a
causing neurodegeneration, may be used to prevent it. more abstract representation of the relation between
synaptic inputs and neuronal firing rate (Segev and Lon-
don, 2000). Two papers in this issue of Neuron (PoiraziGreg M. Cole
et al., 2003a, 2003b) address this question using the
Greater Los Angeles VA Medical Center
example of CA1 pyramidal cells. The results provide
UCLA Alzheimer’s Disease Research Center
a general and explicit method to reduce biophysical
Sepulveda, California 91343
complexity without losing the input/output relation of
single neurons that could potentially lead to a better
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